Haleon (NYSE:HLN) Stock Gets Downgrade from Zacks Research

Haleon (NYSE:HLN) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday, Zacks reports.

Other equities analysts have also issued research reports about the stock. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Friday, September 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research report on Wednesday, September 23rd. Wall Street Zen lowered Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Berenberg Bank reiterated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Haleon has an average rating of “Moderate Buy” and a consensus price target of $4.90.

Haleon Trading Down 0.8%

Shares of HLN stock opened at $10.29 on Thursday. Haleon has a 1-year low of $8.65 and a 1-year high of $11.28. The firm’s 50-day simple moving average is $9.56 and its 200-day simple moving average is $9.51. The firm has a market cap of $45.30 billion, a P/E ratio of 26.37, a PEG ratio of 2.34 and a beta of 0.14. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.69 and a quick ratio of 0.52.

Hedge Funds Weigh In On Haleon

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mondrian Investment Partners LTD acquired a new stake in Haleon in the 3rd quarter valued at $158,737,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of Haleon by 82.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock worth $146,892,000 after purchasing an additional 6,647,329 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Haleon by 27,393.7% during the first quarter. Principal Financial Group Inc. now owns 2,803,530 shares of the company’s stock worth $28,063,000 after purchasing an additional 2,793,333 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Haleon by 17.0% in the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock worth $109,452,000 after buying an additional 1,586,230 shares during the period. Finally, JTC Employer Solutions Trustee Ltd boosted its position in shares of Haleon by 470.2% in the first quarter. JTC Employer Solutions Trustee Ltd now owns 1,610,721 shares of the company’s stock worth $16,115,000 after buying an additional 1,328,217 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.